Aurinia Pharmaceuticals
AUPH
71 hedge funds and large institutions have $176M invested in Aurinia Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 52 funds opening new positions, 13 increasing their positions, 5 reducing their positions, and 6 closing their positions.
872% more capital invested
Capital invested by funds: $18.1M → $176M (+$158M)
767% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 6
184% more funds holding
Funds holding: 25 → 71 (+46)
160% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 5
8.39% more ownership
Funds ownership: 21.72% → 30.11% (+8.4%)
35% less call options, than puts
Call options by funds: $6.29M | Put options by funds: $9.66M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$27M |
| 2 |
O
OrbiMed
New York
|
+$8.3M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$5.77M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$4.62M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$3.65M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$4.29M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3.28M |
| 3 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$2.77M |
| 4 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$1.65M |
| 5 |
SG Americas Securities
New York
|
-$784K |
AUPH Hedge Fund Activity: Q1 2017 in Review
71 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q1 2017, worth a combined $176M — up 872% from $18.1M a quarter earlier.
Buyers outnumbered sellers: 52 funds opened new AUPH positions and 6 closed out — a net gain of 46 holders — while 13 added to existing stakes and 5 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $27M. The largest seller was Goldman Sachs, cutting an estimated $4.29M.
- 71 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q1 2017, up from 25 in Q4 2016.
- Funds reported $176M of Aurinia Pharmaceuticals stock for Q1 2017, up 872% quarter-over-quarter.
- 52 funds opened new Aurinia Pharmaceuticals positions in Q1 2017 and 6 closed out, a net change of +46 holders.
- The largest Aurinia Pharmaceuticals buyer in Q1 2017 was Fidelity Investments, an estimated $27M added.
- The largest Aurinia Pharmaceuticals seller in Q1 2017 was Goldman Sachs, an estimated $4.29M sold.
Based on aggregated 13F filings for Q1 2017.